Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,280.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $10.14, for a total transaction of $20,280.00. Following the completion of the transaction, the president now owns 2,839,260 shares of the company’s stock, valued at approximately $28,790,096.40. The trade was a 0.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.74, for a total transaction of $23,480.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.25, for a total transaction of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total transaction of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total transaction of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.

Gyre Therapeutics Stock Performance

Shares of Gyre Therapeutics stock opened at $11.96 on Friday. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $19.96. The firm has a fifty day moving average of $11.24 and a two-hundred day moving average of $12.32.

Wall Street Analysts Forecast Growth

Separately, Noble Financial began coverage on shares of Gyre Therapeutics in a research report on Tuesday. They set an “outperform” rating for the company.

Hedge Funds Weigh In On Gyre Therapeutics

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in shares of Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Gyre Therapeutics by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company’s stock valued at $1,386,000 after purchasing an additional 918 shares in the last quarter. State Street Corp increased its holdings in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Gyre Therapeutics by 9.1% in the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock valued at $1,251,000 after purchasing an additional 8,624 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in shares of Gyre Therapeutics in the 4th quarter valued at about $1,225,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.